Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 12/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8822111 | 0.89 | CALML3 (0.46) | CALML3MAOAMAOB | |
| SCHEMBL6996844 | 0.85 | CALML3 (0.46) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL7836393 | 0.85 | CALML3 (0.48) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL8822042 | 0.85 | CALML3 (0.47) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL7840408 | 0.83 | CALML3 (0.70) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL1222291 | 0.81 | MAOB (0.50) | CALML3MAOAMAOB | |
| SCHEMBL1222294 | 0.81 | MAOB (0.50) | CALML3MAOAMAOB | |
| SCHEMBL8822103 | 0.80 | MAOA (0.66) | CALML3MAOAMAOB | |
| SCHEMBL18770241 | 0.79 | MAOB (0.48) | CALML3MAOAMAOB | |
| SCHEMBL1032546 | 0.79 | MAOB (0.48) | CALML3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286998-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001081350-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-01 | — | — | WO | disclosed |